Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 9:11:634409.
doi: 10.3389/fimmu.2020.634409. eCollection 2020.

Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease

Affiliations
Review

Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease

Joeri Lambrecht et al. Front Immunol. .

Abstract

In the Western society, non-alcoholic fatty liver disease (NAFLD), characterized by the excessive accumulation of fat in the liver, represents the most common cause of chronic liver disease. If left untreated, approximately 15%-20% of patients with NAFLD will progress to non-alcoholic steatohepatitis (NASH), in which lobular inflammation, hepatocyte ballooning and fibrogenesis further contribute to a distorted liver architecture and function. NASH initiation has significant effects on liver-related mortality, as even the presence of early stage fibrosis increases the chances of adverse patient outcome. Therefore, adequate diagnostic tools for NASH are needed, to ensure that relevant therapeutic actions can be taken as soon as necessary. To date, the diagnostic gold standard remains the invasive liver biopsy, which is associated with several drawbacks such as high financial costs, procedural risks, and inter/intra-observer variability in histology analysis. As liver inflammation is a major hallmark of disease progression, inflammation-related circulating markers may represent an interesting source of non-invasive biomarkers for NAFLD/NASH. Examples for such markers include cytokines, chemokines or shed receptors from immune cells, circulating exosomes related to inflammation, and changing proportions of peripheral blood mononuclear cell (PBMC) subtypes. This review aims at documenting and critically discussing the utility of such novel inflammatory markers for NAFLD/NASH-diagnosis, patient stratification and risk prediction.

Keywords: NAFLD; NASH; biomarker; chronic liver disease; inflammation; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

FT’s lab has received research funding by Allergan, Bristol-Myers Squibb, Galapagos, Gilead and Inventiva. He consults for Allergan, Bayer, Boehringer Ingelheim, Galapagos, Galmed, Intercept, Inventiva, NGM bio, Novartis and Pfizer. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Damaging hits during non-alcoholic fatty liver disease (NAFLD) pathogenesis. The pathogenesis of NAFLD relies on multiple damaging “hits”, including the proliferation, dysfunction and inflammation of adipose tissue, the excessive presence of fatty acids and cholesterol in the liver and circulation, and important changes in gut permeability and microbiota composition causing an increased release of pathogen-associated molecular patterns. Subsequent to these damaging factors, an enhanced production and release of pro-inflammatory cytokines and chemokines is observed, creating a pro-inflammatory environment in which Kupffer cells become activated and monocyte-derived macrophages (MoMФs) and other leukocytes are recruited to the liver.

References

    1. Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut (2018) 67:963–72. 10.1136/gutjnl-2017-315691 - DOI - PMC - PubMed
    1. L. European Association for the Study of the, D. European Association for the Study of, and O European Association for the Study of, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol (2016) 64:1388–402. 10.1016/j.jhep.2015.11.004 - DOI - PubMed
    1. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol (2018) 69:896–904. 10.1016/j.jhep.2018.05.036 - DOI - PubMed
    1. Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother (2020) 4:1–13. 10.1080/14656566.2020.1774553 - DOI - PubMed
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology (2015) 149:389–97 e10. 10.1053/j.gastro.2015.04.043 - DOI - PMC - PubMed

Publication types

MeSH terms